How does TMAN-F's PE Ratio compare to its peers?

TMAN-F is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (22.3x).

How does TMAN-F's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

TMAN-F is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Asian Pharmaceuticals industry average (24.1x).

What is TMAN-F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate TMAN-F's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of TMAN-F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TMAN-F (THB18.7) is trading above our estimate of [[fair value]] (THB6.51)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

T.Man Pharmaceutical (THAMSE:TMAN-F) - Stock Price, News & Analysis

TMAN-F Stock Overview

Manufactures and sells pharmaceuticals and health products. More details

TMAN-F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	3/6
Financial Health	4/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (14.4x) is below the TH market (15x)

Earnings are forecast to grow 17.45% per year

Earnings have grown 30.7% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

T.Man Pharmaceutical Public Company Limited Competitors

Bangkok Lab And Cosmetic

SET:BLC

฿3.2b

Mega Lifesciences

SET:MEGA

฿30.7b

JSP Pharmaceutical Manufacturing (Thailand) Public

SET:JSP

฿1.1b

Animalcare Group

AIM:ANCR

UK£148.5m

Price History & Performance

Summary of all time highs, changes and price drops for T.Man Pharmaceutical
Historical stock prices
Current Share Price	฿18.70
52 Week High	฿18.70
52 Week Low	฿18.70
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	TMAN-F	TH Pharmaceuticals	TH Market
7D	0%	-1.4%	0.3%
1Y	n/a	4.9%	3.2%

Return vs Industry: Insufficient data to determine how TMAN-F performed against the TH Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TMAN-F performed against the TH Market.

Price Volatility

Is TMAN-F's price volatile compared to industry and market?
TMAN-F volatility
TMAN-F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	4.6%
10% most volatile stocks in TH Market	10.1%
10% least volatile stocks in TH Market	2.4%

Stable Share Price: TMAN-F's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: Insufficient data to determine TMAN-F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2023	944	n/a	www.tmanpharma.in.th

T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health products. It offers a range of pharmaceutical products, including antibiotics, gastrointestinal drugs, respiratory drugs, musculoskeletal drugs, nervous system drugs, and chronic disease drugs, as well as medicines for the skin in form of tablets, capsules, powders, liquids, and semisolids. The company was incorporated in 2023 and is headquartered in Bangkok, Thailand.

T.Man Pharmaceutical Public Company Limited Fundamentals Summary

How do T.Man Pharmaceutical's earnings and revenue compare to its market cap?
TMAN-F fundamental statistics
Market cap	฿6.24b
Earnings (TTM)	฿433.28m
Revenue (TTM)	฿2.20b

14.4x

P/E Ratio

2.8x

P/S Ratio

Is TMAN-F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TMAN-F income statement (TTM)
Revenue	฿2.20b
Cost of Revenue	฿1.17b
Gross Profit	฿1.02b
Other Expenses	฿591.41m
Earnings	฿433.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.08
Gross Margin	46.65%
Net Profit Margin	19.73%
Debt/Equity Ratio	42.7%

How did TMAN-F perform over the long term?

See historical performance and comparison

T.Man Pharmaceutical THAMSE:TMAN-F Stock Report